Looking for New Targeted Therapies for Osteosarcoma in Dogs
Signaling pathways are groups of molecules in a cell that work together to control one or more cell functions, such as cell division or cell death. Recent studies have shown that the fibroblast growth factor (FGF) signaling pathway is often abnormally activated in a variety of human tumors. Researchers will explore the role of increased expression of FGF protein molecules in canine osteosarcoma cells. They will then evaluate the effect of inhibiting the FGF pathway with a targeted drug. Understanding how abnormally activated signaling pathways affect cancer’s development and how to reverse their effects on tumor progression and chemotherapy resistance will help in the development of new targeted therapies for dogs with osteosarcoma.
Principal Investigator: Dr. Deanna D. Dailey, Colorado State University
Sponsors: Dr. & Mrs. Martin V. Haspel, Newfoundland Club of America Charitable Trust, Quad W Foundation, Blue Buffalo Foundation, Petco Foundation
Study ID: D15CA-316